Gonadorelin: What the Evidence Actually Shows

Gonadorelin is marketed today mostly as a fertility-preservation add-on for men on testosterone replacement therapy — a way to keep the testicles from shrinking while on TRT. That marketed use sits alongside a genuinely different, and genuinely real, regulatory and research history: this compound once had FDA-approved human drug products, both now discontinued, and its actual published human evidence is built around two different, narrower applications than the one it's sold for today.

What gonadorelin actually is

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH) — the decapeptide the hypothalamus releases to trigger the pituitary gland's release of LH and FSH, the two hormones that drive the entire downstream hormone-production chain in both men and women. It sits one step upstream of the same hypothalamic-pituitary-gonadal (HPG) axis this site's Kisspeptin article covers — kisspeptin triggers GnRH release; gonadorelin is a synthetic version of GnRH itself, one link further down the chain.

A real FDA-approval history — now entirely discontinued

Unlike most compounds in this site's newer-content batches, gonadorelin genuinely did have FDA-approved human drug products. A direct query against FDA's own Drugs@FDA database confirms two separate approved New Drug Applications: FACTREL (gonadorelin hydrochloride, in 0.1 mg, 0.2 mg, and 0.5 mg strengths), approved September 30, 1982, sponsored at various points by different manufacturers, for diagnostic evaluation of hypothalamic-pituitary-gonadal function¹; and LUTREPULSE KIT (gonadorelin acetate, in 0.8 mg and 3.2 mg strengths), approved October 10, 1989 under orphan-drug status, sponsored by Ferring, specifically for pulsatile-pump treatment of primary hypothalamic amenorrhea². Both are real, both were genuinely reviewed and approved by FDA — and both carry the marketing status "Discontinued" on every product row in FDA's own database. No generic version of gonadorelin has ever been approved under any strength. As of today, there is no FDA-approved human gonadorelin product on the U.S. market in any form.

A naming trap worth flagging directly

Here's a genuine, live-confirmed source of confusion: search DailyMed for "Factrel" today and you will find a real, currently-active product filing — but it is not the human drug described above. It is an entirely different, animal-only product: a treatment for ovarian follicular cysts in dairy and beef cattle, labeled explicitly "For use in animals only. Not for human use," approved under a New Animal Drug Application (NADA #139-237, not an NDA), currently sold by Zoetis³. The human NDA018123 Factrel and the veterinary-only Factrel sold today share a brand name by reuse, not by any regulatory continuity — they are two unrelated products from two different eras and two different FDA review pathways. Anyone researching gonadorelin's approval history who stops at a DailyMed search for "Factrel" without checking which product they've actually found risks concluding, incorrectly, that the human product is still on the market. It is not.

What the real published human evidence actually supports

Gonadorelin's genuine, current, published human research base centers on two specific, narrower applications than the fertility-preservation use it's commonly marketed for today. First: the GnRH stimulation test, a real diagnostic tool used to evaluate pituitary gonadotropin reserve — a single dose is given and LH/FSH response is measured, a technique still in active clinical and veterinary use. Second, and more clinically substantial: pulsatile-pump gonadorelin therapy — repeated small doses delivered on a physiologic pulse schedule via an infusion pump — to induce puberty and fertility in men and women with congenital hypogonadotropic hypogonadism, a specific condition where the hypothalamus fails to produce its own pulsatile GnRH signal. Real, published human studies exist here: a 2025 study of pulsatile GnRH pump therapy in male infants with this condition⁴, and a study comparing the pulsatile pump directly against cyclical gonadotropin therapy in adult men with the same condition, finding the pump induced spermatogenesis earlier⁵. Both are genuine, if population-specific, clinical findings — for a rare congenital condition, using a specialized pulsatile-pump delivery method, not the once-or-twice-weekly injection protocol sold in the wellness/TRT market today.

What the market's own marketed use is not backed by

A dedicated PubMed search targeted specifically at gonadorelin as an adjunct given alongside exogenous testosterone therapy — the "fertility preservation" or testicular-function-preservation use it is actually marketed for in TRT clinics — did not turn up a dedicated human trial of that specific protocol. This is the same evidence shape this corpus's Kisspeptin article already documented for a related HPG-axis compound: real, published, narrow clinical evidence exists, for a use that is not the one the wellness market actually sells it for. That does not mean the TRT-adjunct use has been shown not to work — it means nobody has published a dedicated trial testing it, which is a different and more honest thing to say than implying the congenital-hypogonadism pump literature validates it.

The regulatory and safety picture today

Because both approved human products are discontinued and no generic exists, any gonadorelin sold today for human use comes from a compounding pharmacy, not an FDA-approved manufacturer. A live check of FDA's current 503A Bulks List (updated May 14, 2026) and its companion significant-safety-risks page found no mention of gonadorelin in either — it has not been formally nominated for or flagged under FDA's compounding-substance review process. openFDA's FAERS adverse-event database returns 610 total reports for "GONADORELIN," live-queried for this article⁶ — a substantial count consistent with gonadorelin's long history as a widely-used diagnostic and veterinary agent, not a signal this article breaks down further here.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell gonadorelin — this site's own identity-layer research confirms it is not tagged to any reviewed seller. Gonadorelin is a genuinely different case from most of this site's non-board compounds: it has real historical FDA approval, real published human trials, and a real ongoing role in reproductive endocrinology — just not for the specific use, dose schedule, or population it's most commonly marketed for today. If you're researching it alongside other HPG-axis compounds, our Kisspeptin evidence review covers the hormone one step upstream in the same signaling chain, with a strikingly similar finding: real, narrow, published clinical evidence for a use that isn't the one the market actually sells it for. Our reconstitution calculator does the vial-to-syringe arithmetic on whatever numbers you enter — it cannot confirm a dose matches any studied protocol, since no FDA-approved product currently exists to validate one against.